'Hiv ve' presentation slideshows

Progress Towards 3 x 5 Uganda 2003-2005

Progress Towards 3 x 5 Uganda 2003-2005. Geoffrey Taylor Division of Infectious Diseases University of Alberta. DART : triple NRTI ( AZT/3TC/TDF) randomized to lab vs clinical monitoring and to continuous vs interupted therapy 54% <50 copies @ 24 wks.

597 views • 50 slides

Session 2 Observational studies

645 views • 49 slides

Dermatology department

834 views • 47 slides

HIV and AIDS

HIV and AIDS. Dr. R. Senthil. MS FRCS MCh(Urology) Member of Parliament. Role of Parliamentarian. Legislator Budget Allotment Prevention Drugs Treatment Centers / Facilities Rehabilitation Awareness. Natural History. Acute Infection 2 to 3 weeks Recovery + Serovonversion

515 views • 42 slides

Effective pre-test discussion? A case note review

Effective pre-test discussion? A case note review. Mel Ottewill & Dr Zoe Warwick SSHA Conference 2008. Context. HIV +ve patients still dying - non-adherence - late presentation Current national targets to reduce late presentation Within GU clinics by end 2007

530 views • 35 slides

Early Treatment: cases

429 views • 35 slides

HIV & Subfertility

HIV & Subfertility. Leila C G Frodsham Clinical Research Fellow Assisted Conception Unit Chelsea and Westminster. Talk to UK-CAB (UK-Community Advisory Board) 25 October, 2002 HIV I-Base: http://www.I-base.org.uk. Our Team. Leila CG Frodsham Research Fellow Bronwen Tamberlin

466 views • 34 slides

HIV & TUBERCULOSIS ( The Double Menace ) ( World AIDS Day ) December 1

HIV & TUBERCULOSIS ( The Double Menace ) ( World AIDS Day ) December 1. By Dr.K.Bujjibabu . M.D. OVERVIEW. Emergence of HIV epidemic posed major challenge to TB control efforts. Co-infection of HIV & TB worldwide- 5-6 Million ( 90% in developing countries )

461 views • 31 slides

Preventing recurrent TB in high HIV-prevalent areas

Preventing recurrent TB in high HIV-prevalent areas. What are the options for TB Control Programmes?. DEFINITION OF RECURRENT TB. TB which re-occurs after a patient has been previously diagnosed with TB and completed a full course of treatment

246 views • 24 slides

Cotrimoxazole and INH preventive therapies in the era of ART: are they necessary?

Cotrimoxazole and INH preventive therapies in the era of ART: are they necessary?. Anthony D Harries Ministry of Health, Malawi. I DO NOT KNOW!. Cotrimoxazole. COTRIMOXAZOLE (CTX) PROPHYLAXIS. Useful against:- Pneumocystis jiroveci (carinii) pneumonia Toxoplasma encephalitis

222 views • 21 slides

CASCADE: AIDS or death

When to start antiretroviral therapy Julian Elliott Department of Infectious Diseases, Alfred Hospital and Monash University Centre for Population Health, Burnet Institute Melbourne ASHM Early Treatment Webinar, Melbourne, March 2014. CASCADE: AIDS or death. D:A:D Study:

325 views • 17 slides

The brain of a child: Understanding cognitive development for children living with HIV

The brain of a child: Understanding cognitive development for children living with HIV. Prof Lorraine Sherr, University College London Member Coalition for Children Affected by AIDS. Presentation AIM.

185 views • 17 slides

HIV CASE PRESENTATIONS: SARAH BARBER CNS HIV. 01689 866647

266 views • 14 slides

DOTS WORKS VWSA WORKPLACE PROGRAM

231 views • 12 slides

TB/HIV COLLABORATION IN UGANDA

TB/HIV COLLABORATION IN UGANDA. PRESENTED BY DR HENRY LUWAGA. BACKGROUND. Population 25M Adult HIV Prevalence 6.1% PLWHA estimated to be 1M TB burden estimated at 150-160 smear positive cases per 100,000 50% of TB patients are HIV +ve There was need to improve care for TB/HIV clients.

112 views • 9 slides